Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 166 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2016', provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
- The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects
- The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Systemic Sclerosis (Scleroderma) Overview 10
Therapeutics Development 11
Pipeline Products for Systemic Sclerosis (Scleroderma) - Overview 11
Pipeline Products for Systemic Sclerosis (Scleroderma) - Comparative Analysis 12
Systemic Sclerosis (Scleroderma) - Therapeutics under Development by Companies 13
Systemic Sclerosis (Scleroderma) - Therapeutics under Investigation by Universities/Institutes 15
Systemic Sclerosis (Scleroderma) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Systemic Sclerosis (Scleroderma) - Products under Development by Companies 19
Systemic Sclerosis (Scleroderma) - Products under Investigation by Universities/Institutes 21
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 22
Allergan Plc 22
Angion Biomedica Corp. 23
arGentis Pharmaceuticals, LLC 24
Bayer AG 25
BioLineRx, Ltd. 26
BiOrion Technologies B.V. 27
Boehringer Ingelheim GmbH 28
Bristol-Myers Squibb Company 29
Corbus pharmaceuticals, Inc. 30
CSL Limited 31
Daval International Limited 32
Digna Biotech, S.L. 33
F. Hoffmann-La Roche Ltd. 34
Fibrocell Science, Inc. 35
GenKyoTex S.A. 36
GlaxoSmithKline Plc 37
iBio, Inc. 38
Inventiva SAS 39
Kadmon Corporation, LLC 40
miRagen Therapeutics, Inc. 41
Peptinov SAS 42
Ribomic Inc. 43
Stratatech Corporation 44
Vida Therapeutics Inc. 45
VivaCell Biotechnology Espana S.L. 46
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
abatacept - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
acALY-18 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
acetylcysteine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Aimspro - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ANG-3070 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ARG-201 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
belimumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BL-1110 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
BOT-191 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
C-82 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Cell Therapy for Dermatology and Immunology - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
disitertide - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
factor XIII (human) - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
FCX-013 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
GKT-831 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
GSK-2330811 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
IBIOCFB-03 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
IVA-337 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
JBT-101 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
KD-025 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MGN-4220 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
nintedanib - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Oligonucleotide for Scleroderma - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
onabotulinumtoxin A - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
PAT-048 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
PDX-002 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
PPV-06 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
RBM-006 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
riociguat - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Small Molecule to Inhibit NFkB for Immunology and Oncology - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
tocilizumab - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
VCE-0048 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
VEDA-1209 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
VTI-1000 Series - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Systemic Sclerosis (Scleroderma) - Recent Pipeline Updates 120
Systemic Sclerosis (Scleroderma) - Dormant Projects 156
Systemic Sclerosis (Scleroderma) - Discontinued Products 158
Systemic Sclerosis (Scleroderma) - Product Development Milestones 159
Featured News & Press Releases 159
Dec 08, 2015: New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis 159
Nov 12, 2015: miRagen Therapeutics Initiates First Clinical Trial for Anti-Fibrosis Product Candidate MRG-201 159
Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis 160
Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum 161
Oct 07, 2015: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis 161
Aug 31, 2015: Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab for the Treatment of Systemic Sclerosis 161
Aug 19, 2015: Corbus Pharmaceuticals' Investigational Drug Resunab Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis 163
Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015 163
Aug 06, 2015: Data On PDX-002 Published In Biomaterials Journal 164
Jun 12, 2015: Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab for the Treatment of Systemic Sclerosis (Scleroderma) 164
Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 165
Disclaimer 166

List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2016 11
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Development by Companies, H1 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H1 2016 22
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp., H1 2016 23
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals, LLC, H1 2016 24
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H1 2016 25
Systemic Sclerosis (Scleroderma) - Pipeline by BioLineRx, Ltd., H1 2016 26
Systemic Sclerosis (Scleroderma) - Pipeline by BiOrion Technologies B.V., H1 2016 27
Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 28
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H1 2016 29
Systemic Sclerosis (Scleroderma) - Pipeline by Corbus pharmaceuticals, Inc., H1 2016 30
Systemic Sclerosis (Scleroderma) - Pipeline by CSL Limited, H1 2016 31
Systemic Sclerosis (Scleroderma) - Pipeline by Daval International Limited, H1 2016 32
Systemic Sclerosis (Scleroderma) - Pipeline by Digna Biotech, S.L., H1 2016 33
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 34
Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science, Inc., H1 2016 35
Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex S.A., H1 2016 36
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H1 2016 37
Systemic Sclerosis (Scleroderma) - Pipeline by iBio, Inc., H1 2016 38
Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva SAS, H1 2016 39
Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corporation, LLC, H1 2016 40
Systemic Sclerosis (Scleroderma) - Pipeline by miRagen Therapeutics, Inc., H1 2016 41
Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H1 2016 42
Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc., H1 2016 43
Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corporation, H1 2016 44
Systemic Sclerosis (Scleroderma) - Pipeline by Vida Therapeutics Inc., H1 2016 45
Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016 46
Assessment by Monotherapy Products, H1 2016 47
Number of Products by Stage and Target, H1 2016 49
Number of Products by Stage and Mechanism of Action, H1 2016 52
Number of Products by Stage and Route of Administration, H1 2016 55
Number of Products by Stage and Molecule Type, H1 2016 57
Systemic Sclerosis (Scleroderma) Therapeutics - Recent Pipeline Updates, H1 2016 120
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2016 156
Systemic Sclerosis (Scleroderma) - Dormant Projects (Contd..1), H1 2016 157
Systemic Sclerosis (Scleroderma) - Discontinued Products, H1 2016 158